Proteomic profiling defines biologically and clinically distinct pACT subtypes that provide prognostic information beyond histopathology. This framework enables proteome-based stratification, identifi...

Ketoacidosis risk with SGLT2 inhibitors varies greatly by patient characteristics and is not confined to early in treatment. Risk should be assessed throughout treatment, and patients should be instru...

Adrenal tumours have become a common incidental finding in the radiological evaluation of patients. Estimates suggest that 1–10% of the general population currently harbours an adrenal tumour, peaking...

This TimeCapsule reviews the major transformations in lipid metabolism and cardiovascular disease prevention during the first quarter of the 21st century and their impact on clinical practice. From la...

Pemafibrate demonstrated greater reductions in ALT levels than fenofibrate, with a notable dose–response relationship and favorable safety profile, suggesting therapeutic potential for patients with M...

We provide population-level cross-sectional prevalence data on clinical obesity, which were largely consistent across diverse high-income settings. The findings highlight challenges in operationalisin...

In recent decades, life expectancy among people with type 1 diabetes has improved substantially in many high-income countries and well resourced health-care settings, highlighting persistent global in...

In this trial involving adults with type 1 diabetes, dual-hormone fully closed-loop therapy resulted in an increase in time in range compared to multiple daily insulin injections therapy, but not comp...

High remission rates signal feasibility and efficacy of a combined LED and intensive exercise intervention in EOT2D, justifying examination of synergistic benefits beyond remission.

Type 2 diabetes is a heterogeneous, progressive chronic condition for which management has traditionally focused on glycaemic control and cardiovascular risk factors, rather than focusing on altering ...

Despite robust Treg expansion confirming target engagement, low-dose IL-2 did not preserve β-cell function in people with newly diagnosed type 1 diabetes. The inflammatory environment at diagnosis mig...

Current BMI-based measures of obesity can both underestimate and overestimate adiposity and provide inadequate information about health at the individual level, which undermines medically-sound approa...

The global prevalence of diabetes is rising rapidly, with the steepest increases and greatest unmet need occurring in low-income and middle-income countries. Despite strong evidence that early detecti...

Type 2 diabetes is a heterogeneous, progressive chronic condition for which management has traditionally focused on glycaemic control and cardiovascular risk factors, rather than focusing on altering ...

Despite robust Treg expansion confirming target engagement, low-dose IL-2 did not preserve β-cell function in people with newly diagnosed type 1 diabetes. The inflammatory environment at diagnosis mig...

Artificial intelligence (AI) use in diabetes care is increasingly being explored to personalise care for people with diabetes and adapt treatments for complex presentations. However, the rapid advance...

Treatment with retatrutide resulted in substantial improvements in bodyweight and was associated with improvements in glycaemic control in participants with obesity and type 2 diabetes, with a safety ...

In people with type 2 diabetes at increased cardiovascular risk, the cardiovascular safety of orforglipron was confirmed by demonstrating non-inferiority to insulin glargine for MACE-4. Gastrointestin...

Mauritius is the first country to show a decreasing prevalence of type 2 diabetes and intermediate hyperglycaemia over time, using the objective, gold standard OGTT-based diagnostic criteria recommend...

Paediatric obesity remains one of the greatest public health challenges of the 21st century. In England, the National Child Measurement Programme 2024–25 report found that 10·5% of children aged 4–5 y...

Glucagon-like peptide-1 (GLP-1) receptor agonists are transforming the management of obesity and metabolic disease, with important implications across women’s health.

Type 2 diabetes is a heterogeneous, progressive chronic condition for which management has traditionally focused on glycaemic control and cardiovascular risk factors, rather than focusing on altering ...

YouTube video by The Lancet

Data pooled from three large phase 3 trials suggest that semaglutide reduces the risk of major kidney outcomes in a broad population with cardio–kidney–metabolic disease while having a favourable risk...

In Spanish pre-schoolers UPF-related metabolomic profiles were associated with different cardiovascular risk factors. These diet-related metabolomic scores capture biological correlates relevant to ea...

This 13-year follow-up of a prespecified secondary outcome of the COPSAC2010 vitamin D RCT did not show any lasting effect on offspring bone mineral content until age 13 years.

Overnight metyrapone was well tolerated and associated with partial restoration of HPA axis balance and improved sleep and mood. These findings support further controlled evaluation of metyrapone in M...